{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:33:15Z","timestamp":1788445995767,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005888","name":"Uniwersytet Medyczny w Lodzi","doi-asserted-by":"crossref","award":["503\/1-034-03\/503-11-001"],"award-info":[{"award-number":["503\/1-034-03\/503-11-001"]}],"id":[{"id":"10.13039\/501100005888","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005888","name":"Uniwersytet Medyczny w Lodzi","doi-asserted-by":"crossref","award":["503\/1-034-03\/503-11-001"],"award-info":[{"award-number":["503\/1-034-03\/503-11-001"]}],"id":[{"id":"10.13039\/501100005888","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005888","name":"Uniwersytet Medyczny w Lodzi","doi-asserted-by":"crossref","award":["503\/1-034-03\/503-11-001"],"award-info":[{"award-number":["503\/1-034-03\/503-11-001"]}],"id":[{"id":"10.13039\/501100005888","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14976-2","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T13:13:31Z","timestamp":1759756411000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["High FGFR4 protein expression, but not FGFR1 or FGFR2, predicts poor prognosis in pancreatic ductal adenocarcinoma"],"prefix":"10.1186","volume":"25","author":[{"given":"Marcin","family":"Braun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Dur\u015blewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"So\u0142ek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzanna","family":"Nowicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Zieli\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Antosik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariusz","family":"Grzanka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"issue":"1","key":"14976_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"14976_CR2","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","volume":"17","author":"WJ Ho","year":"2020","unstructured":"Ho WJ, Jaffee EM, Zheng L. The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities. Nat Rev Clin Oncol. 2020;17(9):527\u201340.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"14976_CR3","first-page":"491","volume":"42","author":"AS Coetzee","year":"2023","unstructured":"Coetzee AS, Carter EP, Rodr\u00edguez-Fern\u00e1ndez L, Heward J, Wang Q, Karim SA, et al. Nuclear FGFR1 promotes pancreatic stellate cell-driven invasion through up-regulation of neuregulin 1. Oncogene. 2023;42(7):491\u2013500.","journal-title":"Oncogene"},{"issue":"4","key":"14976_CR4","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3390\/cells10040847","volume":"10","author":"EP Carter","year":"2021","unstructured":"Carter EP, Coetzee AS, Tomas Bort E, Wang Q, Kocher HM, Grose RP. Dissecting FGF signalling to target cellular crosstalk in pancreatic cancer. Cells. 2021;10(4):847.","journal-title":"Cells"},{"issue":"1","key":"14976_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00683-x","volume":"8","author":"L Stein","year":"2024","unstructured":"Stein L, Murugesan K, Reeser JW, Risch Z, Wing MR, Paruchuri A, et al. Fgfr2-fusions define a clinically actionable molecular subset of pancreatic cancer. NPJ Precis Oncol. 2024;8(1):207.","journal-title":"NPJ Precis Oncol"},{"key":"14976_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-244271","author":"D Poon","year":"2021","unstructured":"Poon D, Tan MH, Khor D. Stage 4 pancreatic adenocarcinoma harbouring an FGFR2-TACC2 fusion mutation with complete response to erdafitinib a pan-fibroblastic growth factor receptor inhibitor. BMJ Case Rep. 2021. https:\/\/doi.org\/10.1136\/bcr-2021-244271.","journal-title":"BMJ Case Rep"},{"key":"14976_CR7","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ejca.2022.09.016","volume":"176","author":"C Helal","year":"2022","unstructured":"Helal C, Valery M, Ducreux M, Hollebecque A, Smolenschi C. FGFR2 fusion in metastatic pancreatic ductal adenocarcinoma: is there hope? Eur J Cancer. 2022;176:168\u201370.","journal-title":"Eur J Cancer"},{"issue":"10","key":"14976_CR8","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.6004\/jnccn.2022.7039","volume":"20","author":"CF Ng","year":"2022","unstructured":"Ng CF, Glaspy J, Placencio-Hickok VR, Thomassian S, Gong J, Osipov A, et al. Exceptional response to erdafitinib in FGFR2-mutated metastatic pancreatic ductal adenocarcinoma. J Natl Compr Canc Netw. 2022;20(10):1076\u20139.","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"14976_CR9","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1158\/2767-9764.CRC-24-0137","volume":"4","author":"B Garmezy","year":"2024","unstructured":"Garmezy B, Borad MJ, Bahleda R, Perez CA, Chen LT, Kato S, et al. A phase I study of KIN-3248, an irreversible small-molecule pan-FGFR inhibitor, in patients with advanced FGFR2\/3-driven solid tumors. Cancer Res Commun. 2024;4(4):1165\u201373.","journal-title":"Cancer Res Commun"},{"issue":"9","key":"14976_CR10","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1111\/bph.16289","volume":"181","author":"Q Lin","year":"2024","unstructured":"Lin Q, Serratore A, Perri J, Roy Chaudhuri T, Qu J, Ma WW, et al. Expression of fibroblast growth factor receptor 1 correlates inversely with the efficacy of single-agent fibroblast growth factor receptor-specific inhibitors in pancreatic cancer. Br J Pharmacol. 2024;181(9):1383\u2013403.","journal-title":"Br J Pharmacol"},{"issue":"3","key":"14976_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12605","volume":"52","author":"X Kang","year":"2019","unstructured":"Kang X, Lin Z, Xu M, Pan J, Wang ZW. Deciphering role of FGFR signalling pathway in pancreatic cancer. Cell Prolif. 2019;52(3):e12605.","journal-title":"Cell Prolif"},{"issue":"1","key":"14976_CR12","first-page":"133","volume":"38","author":"N Motoda","year":"2011","unstructured":"Motoda N, Matsuda Y, Onda M, Ishiwata T, Uchida E, Naito Z. Overexpression of fibroblast growth factor receptor 4 in high-grade pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Int J Oncol. 2011;38(1):133\u201343.","journal-title":"Int J Oncol"},{"issue":"38","key":"14976_CR13","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1038\/s41388-022-02432-5","volume":"41","author":"S D\u2019Agosto","year":"2022","unstructured":"D\u2019Agosto S, Pezzini F, Veghini L, Delfino P, Fiorini C, Temgue Tane GD, et al. Loss of FGFR4 promotes the malignant phenotype of PDAC. Oncogene. 2022;41(38):4371\u201384.","journal-title":"Oncogene"},{"key":"14976_CR14","doi-asserted-by":"publisher","unstructured":"Neska-Dlugosz I, Buchholz K, Durslewicz J, Gagat M, Grzanka D, Tojek K et al. Prognostic impact and functional annotations of KIF11 and KIF14 expression in patients with colorectal cancer. Int J Mol Sci. 2021;22(18). https:\/\/doi.org\/10.3390\/ijms22189732.","DOI":"10.3390\/ijms22189732"},{"issue":"10","key":"14976_CR15","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1007\/s00432-020-03314-7","volume":"146","author":"A Gzil","year":"2020","unstructured":"Gzil A, Zarebska I, Jaworski D, Antosik P, Durslewicz J, Maciejewska J, et al. The prognostic value of leucine-rich repeat-containing G-protein (Lgr5) and its impact on clinicopathological features of colorectal cancer. J Cancer Res Clin Oncol. 2020;146(10):2547\u201357.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"8","key":"14976_CR16","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1111\/cts.13563","volume":"16","author":"M Posta","year":"2023","unstructured":"Posta M, Gy\u0151rffy B. Analysis of a large cohort of pancreatic cancer transcriptomic profiles to reveal the strongest prognostic factors. Clin Transl Sci. 2023;16(8):1479\u201391.","journal-title":"Clin Transl Sci"},{"issue":"5","key":"14976_CR17","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cbio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401\u20134.","journal-title":"Cancer Discov"},{"issue":"W1","key":"14976_CR18","doi-asserted-by":"publisher","first-page":"W207","DOI":"10.1093\/nar\/gkad347","volume":"51","author":"L Kolberg","year":"2023","unstructured":"Kolberg L, Raudvere U, Kuzmin I, Adler P, Vilo J, Peterson H. g:Profiler-interoperable web service for functional enrichment analysis and gene identifier mapping (2023 update). Nucleic Acids Res. 2023;51(W1):W207\u201312.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"14976_CR19","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","volume":"18","author":"D Aran","year":"2017","unstructured":"Aran D, Hu Z, Butte AJ. Xcell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18(1):220.","journal-title":"Genome Biol"},{"issue":"3","key":"14976_CR20","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0197-2456(00)00046-5","volume":"21","author":"JM Lachin","year":"2000","unstructured":"Lachin JM. Statistical considerations in the intent-to-treat principle. Control Clin Trials. 2000;21(3):167\u201389.","journal-title":"Control Clin Trials"},{"issue":"W1","key":"14976_CR21","doi-asserted-by":"publisher","first-page":"W566","DOI":"10.1093\/nar\/gkv468","volume":"43","author":"T Metsalu","year":"2015","unstructured":"Metsalu T, Vilo J. Clustvis: a web tool for visualizing clustering of multivariate data using principal component analysis and heatmap. Nucleic Acids Res. 2015;43(W1):W566-70.","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"14976_CR22","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.cell.2018.03.034","volume":"173","author":"TM Malta","year":"2018","unstructured":"Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, et al. Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell. 2018;173(2):338\u201354. e15.","journal-title":"Cell"},{"issue":"1","key":"14976_CR23","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s12029-025-01214-y","volume":"56","author":"N Seraji","year":"2025","unstructured":"Seraji N, Berger I. FGFR as a predictive marker for targeted therapy in gastrointestinal malignancies: a systematic review. J Gastrointest Cancer. 2025;56(1):96.","journal-title":"J Gastrointest Cancer"},{"issue":"20","key":"14976_CR24","first-page":"4741","volume":"53","author":"MS Kobrin","year":"1993","unstructured":"Kobrin MS, Yamanaka Y, Friess H, Lopez ME, Korc M. Aberrant expression of type i fibroblast growth factor receptor in human pancreatic adenocarcinomas. Cancer Res. 1993;53(20):4741\u20134.","journal-title":"Cancer Res"},{"issue":"1","key":"14976_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00222-7","volume":"5","author":"Y Xie","year":"2020","unstructured":"Xie Y, Su N, Yang J, Tan Q, Huang S, Jin M, et al. FGF\/FGFR signaling in health and disease. Signal Transduct Target Ther. 2020;5(1):181.","journal-title":"Signal Transduct Target Ther"},{"key":"14976_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101064","volume":"73","author":"Q Lin","year":"2024","unstructured":"Lin Q, Serratore A, Niu J, Shen S, Roy Chaudhuri T, Ma WW, et al. Fibroblast growth factor receptor 1 inhibition suppresses pancreatic cancer chemoresistance and chemotherapy-driven aggressiveness. Drug Resist Updat. 2024;73:101064.","journal-title":"Drug Resist Updat"},{"issue":"4","key":"14976_CR27","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/emmm.201302698","volume":"6","author":"SJ Coleman","year":"2014","unstructured":"Coleman SJ, Chioni AM, Ghallab M, Anderson RK, Lemoine NR, Kocher HM, et al. Nuclear translocation of FGFR1 and FGF2 in pancreatic stellate cells facilitates pancreatic cancer cell invasion. EMBO Mol Med. 2014;6(4):467\u201381.","journal-title":"EMBO Mol Med"},{"issue":"4","key":"14976_CR28","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/S1091-255X(02)00036-7","volume":"6","author":"SM Vickers","year":"2002","unstructured":"Vickers SM, Huang ZQ, MacMillan-Crow L, Greendorfer JS, Thompson JA. Ligand activation of alternatively spliced fibroblast growth factor receptor-1 modulates pancreatic adenocarcinoma cell malignancy. J Gastrointest Surg. 2002;6(4):546\u201353.","journal-title":"J Gastrointest Surg"},{"issue":"1","key":"14976_CR29","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1186\/s12967-018-1743-9","volume":"16","author":"F Haq","year":"2018","unstructured":"Haq F, Sung YN, Park I, Kayani MA, Yousuf F, Hong SM, et al. FGFR1 expression defines clinically distinct subtypes in pancreatic cancer. J Transl Med. 2018;16(1):374.","journal-title":"J Transl Med"},{"issue":"5","key":"14976_CR30","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1016\/j.ajpath.2012.01.020","volume":"180","author":"T Ishiwata","year":"2012","unstructured":"Ishiwata T, Matsuda Y, Yamamoto T, Uchida E, Korc M, Naito Z. Enhanced expression of fibroblast growth factor receptor 2 IIIc promotes human pancreatic cancer cell proliferation. Am J Pathol. 2012;180(5):1928\u201341.","journal-title":"Am J Pathol"},{"key":"14976_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092713","author":"M Braun","year":"2020","unstructured":"Braun M, Piasecka D, Tomasik B, Mieczkowski K, Stawiski K, Zielinska A, et al. Hormonal receptor status determines prognostic significance of FGFR2 in invasive breast carcinoma. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12092713.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"14976_CR32","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/35083041","volume":"3","author":"U Cavallaro","year":"2001","unstructured":"Cavallaro U, Niedermeyer J, Fuxa M, Christofori G. N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signalling. Nat Cell Biol. 2001;3(7):650\u20137.","journal-title":"Nat Cell Biol"},{"issue":"1","key":"14976_CR33","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12943-025-02408-5","volume":"24","author":"KJ Crawford","year":"2025","unstructured":"Crawford KJ, Humphrey KS, Cortes E, Wang J, Kumarasamy V, Wan Y, et al. Targeting FGFR4 abrogates HNF1A-driven metastasis in pancreatic ductal adenocarcinoma. Mol Cancer. 2025;24(1):208.","journal-title":"Mol Cancer"},{"key":"14976_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102976","author":"N Sasaki","year":"2020","unstructured":"Sasaki N, Gomi F, Yoshimura H, Yamamoto M, Matsuda Y, Michishita M, et al. FGFR4 inhibitor BLU9931 attenuates pancreatic cancer cell proliferation and invasion while inducing senescence: evidence for senolytic therapy potential in pancreatic cancer. Cancers. 2020. https:\/\/doi.org\/10.3390\/cancers12102976.","journal-title":"Cancers"},{"issue":"1","key":"14976_CR35","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s13046-019-1236-6","volume":"38","author":"D Piasecka","year":"2019","unstructured":"Piasecka D, Braun M, Kitowska K, Mieczkowski K, Kordek R, Sadej R, et al. FGFs\/FGFRs-dependent signalling in regulation of steroid hormone receptors - implications for therapy of luminal breast cancer. J Exp Clin Cancer Res. 2019;38(1):230.","journal-title":"J Exp Clin Cancer Res"},{"key":"14976_CR36","doi-asserted-by":"crossref","unstructured":"Lu\u00eds Felipe L, Luiz FCA, Lucas Diniz da C, Mariana Macambira N, Marcos B, Erick FS et al. Disease-free survival as a surrogate for overall survival in early-stage pancreatic cancer trials: a correlation meta-analysis. BMJ Oncology. 2025;4(1):e000766.","DOI":"10.1136\/bmjonc-2025-000766"},{"issue":"1","key":"14976_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-06910-5","volume":"20","author":"RC Nie","year":"2020","unstructured":"Nie RC, Zou XB, Yuan SQ, Chen YB, Chen S, Chen YM, et al. Disease-free survival as a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a meta-analysis of 20 randomized controlled trials. BMC Cancer. 2020;20(1):421.","journal-title":"BMC Cancer"},{"issue":"11","key":"14976_CR38","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.hpb.2017.07.005","volume":"19","author":"F Petrelli","year":"2017","unstructured":"Petrelli F, Tomasello G, Ghidini M, Lonati V, Passalacqua R, Barni S. Disease-free survival is not a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a systematic review of randomized trials. HPB. 2017;19(11):944\u201350.","journal-title":"HPB"},{"issue":"10 Pt A","key":"14976_CR39","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/j.ejso.2020.06.013","volume":"46","author":"F Guerra","year":"2020","unstructured":"Guerra F, Barucca V, Coletta D. Metastases or primary recurrence to the lung is related to improved survival of pancreatic cancer as compared to other sites of dissemination. Results of a systematic review with meta-analysis. Eur J Surg Oncol. 2020;46(10 Pt A):1789\u201394.","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"14976_CR40","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.pan.2024.06.004","volume":"24","author":"JM Levine","year":"2024","unstructured":"Levine JM, Rompen IF, Franco JC, Swett B, Kryschi MC, Habib JR, et al. The impact of metastatic sites on survival rates and predictors of extended survival in patients with metastatic pancreatic cancer. Pancreatology. 2024;24(6):887\u201393.","journal-title":"Pancreatology"},{"issue":"2","key":"14976_CR41","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1245\/s10434-011-2020-9","volume":"19","author":"S Hata","year":"2012","unstructured":"Hata S, Sakamoto Y, Yamamoto Y, Nara S, Esaki M, Shimada K, et al. Prognostic impact of postoperative serum CA 19\u2009\u2013\u20099 levels in patients with resectable pancreatic cancer. Ann Surg Oncol. 2012;19(2):636\u201341.","journal-title":"Ann Surg Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14976-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14976-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14976-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T13:13:33Z","timestamp":1759756413000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14976-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14976"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14976-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Collegium Medicum in Bydgoszcz of the Nicolaus Copernicus University in Torun (approval number KB 342\/2020). Informed consent necessity was waived in accordance with national applicable regulations for studies involving retrospective, anonymized material.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1519"}}